Verona Pharma plc (VRNA)
NASDAQ: VRNA · Real-Time Price · USD
104.90
+0.12 (0.11%)
At close: Jul 18, 2025, 4:00 PM
104.96
+0.06 (0.06%)
After-hours: Jul 18, 2025, 5:38 PM EDT
Verona Pharma Stock Forecast
Stock Price Forecast
The 11 analysts that cover Verona Pharma stock have a consensus rating of "Buy" and an average price target of $114.1, which forecasts a 8.77% increase in the stock price over the next year. The lowest target is $57 and the highest is $170.
Price Target: $114.1 (+8.77%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Verona Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 3 |
| Buy | 3 | 3 | 1 | 1 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 5 | 5 | 8 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $90 → $107 | Strong Buy → Hold | Downgrades | $90 → $107 | +2.00% | Jul 14, 2025 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $138 → $107 | Buy → Hold | Downgrades | $138 → $107 | +2.00% | Jul 10, 2025 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 10, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $140 → $107 | Strong Buy → Hold | Downgrades | $140 → $107 | +2.00% | Jul 9, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $107 | Strong Buy → Hold | Downgrades | $107 | +2.00% | Jul 9, 2025 |
Financial Forecast
Revenue This Year
420.23M
from 42.28M
Increased by 893.94%
Revenue Next Year
730.21M
from 420.23M
Increased by 73.76%
EPS This Year
0.21
from -2.16
EPS Next Year
1.54
from 0.21
Increased by 635.37%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 491.4M | 943.3M | 1.3B | ||
| Avg | 420.2M | 730.2M | 1.0B | ||
| Low | 361.7M | 545.6M | 747.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1,062.3% | 124.5% | 73.1% | ||
| Avg | 893.9% | 73.8% | 42.0% | ||
| Low | 755.5% | 29.8% | 2.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.70 | 3.98 | 4.76 |
| Avg | 0.21 | 1.54 | 3.07 |
| Low | -0.11 | 0.37 | 0.46 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 1,803.2% | 209.3% |
| Avg | - | 635.4% | 99.3% |
| Low | - | 78.1% | -70.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.